Hervé Brailly, CEO, is invited to the panel discussion "French Public Markets – Breakthrough Technologies Panel".
Zurich,Switzerland
More info
Innate Pharma announces its turnover for the first quarter of 2009 and updates on its cash situation
May 5, 2009
- 2.5 million euros in turnover in the first quarter ending March 31, 2009
- 35.4 million euros in cash and cash equivalent as at March 31, 2009 (excluding 4.4 million euros in research tax credit refunded in April 2009)
- A total of 10.4 million euros in research tax credit refund since January 1, 2009
| Download Area |
|---|
| PR in english |
| CP en français |